Company Overview
Snapshot
Founded in March 2020 by Yoav Nissan-cohen and Gal Lenz, Teracyte Analytics is a Health Tech & Life Sciences startup with 11–50 employees. The company has raised $1.5M across one funding round, with the Israel Innovation Authority as an investor. In January 2022, the company secured funding from the Israel Innovation Authority.
Business overview
Teracyte Analytics has developed a platform for high-throughput temporal analysis of live single-cells, utilizing proprietary array chips, an imaging system, and analytical tools. This technology enables the capture and retention of suspension cells in dedicated arrays, alongside real-time monitoring of cell function with high-sensitivity fluorescent and brightfield imaging. The company's AI models are designed to differentiate cell types, count cells, and identify cell-cell interactions, serving the discovery, development, and manufacturing processes for cell therapies, biological drugs, and small molecule drugs within the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Teracyte Analytics' core technology?
- Teracyte Analytics has developed a platform for high-throughput temporal analysis of live single-cells, based on proprietary array chips, an imaging system, and analytical tools. This system allows for real-time monitoring of cell function with high sensitivity.
- When was Teracyte Analytics founded?
- Teracyte Analytics was founded in March 2020 by co-founders Yoav Nissan-cohen and Gal Lenz.
- What is the primary application of Teracyte Analytics' AI models?
- Teracyte Analytics' AI models are capable of distinguishing between various cell types, counting cells, and identifying cell-cell interactions. This technology is applicable in the discovery, development, and manufacturing of cell therapies, biological drugs, and small molecule drugs.
- Which industries does Teracyte Analytics serve?
- Teracyte Analytics serves the biotechnology and pharmaceutical industries, focusing on applications for cell therapies, biological drugs, and small molecule drugs.
- What was a significant early funding event for Teracyte Analytics?
- In January 2022, Teracyte Analytics secured a grant from the Israel Innovation Authority, contributing to its total raised capital of $1.5M.